TG Therapeutics
TGTX
91 hedge funds and large institutions have $178M invested in TG Therapeutics in 2016 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 10 closing their positions.
100% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 10
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
12% more funds holding
Funds holding: 81 → 91 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less capital invested
Capital invested by funds: $252M → $178M (-$73.5M)
88% less call options, than puts
Call options by funds: $115K | Put options by funds: $962K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$15.1M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$8.72M |
| 3 |
Millennium Management
New York
|
+$1.61M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.24M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$13M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.48M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.53M |
| 4 |
VAM
Visium Asset Management
New York
|
-$4.47M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.95M |
TGTX Hedge Fund Activity: Q2 2016 in Review
91 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2016, worth a combined $178M — down 29% from $252M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TGTX positions and 10 closed out — a net gain of 10 holders — while 29 added to existing stakes and 23 trimmed.
The largest buyer was Bridger Management, adding an estimated $15.1M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $13M sold.
- 91 institutional investors held TG Therapeutics (TGTX) as of Q2 2016, up from 81 in Q1 2016.
- Funds reported $178M of TG Therapeutics stock for Q2 2016, down 29% quarter-over-quarter.
- 20 funds opened new TG Therapeutics positions in Q2 2016 and 10 closed out, a net change of +10 holders.
- The largest TG Therapeutics buyer in Q2 2016 was Bridger Management, an estimated $15.1M added.
- The largest TG Therapeutics seller in Q2 2016 was Sectoral Asset Management, an estimated $13M sold.
Based on aggregated 13F filings for Q2 2016.